Neurocognitive Mechanisms of Sentence Production Impairment in Aphasia
Launched by UNIVERSITY OF MARYLAND, COLLEGE PARK · May 6, 2024
Trial Information
Current as of August 21, 2025
Recruiting
Keywords
ClinConnect Summary
This clinical trial is studying how stroke affects a person's ability to produce sentences, which is often seen in a condition called aphasia. Aphasia can make it difficult for individuals to communicate after they have had a stroke, and this can significantly impact their quality of life. The goal of the research is to better understand the brain processes involved in sentence production, which could help develop new treatments for those affected by aphasia. The study is currently looking for participants, including adults aged 18 and older who have experienced a stroke and have developed aphasia, as well as healthy individuals either younger (ages 18-30) or older (over 60).
To participate, individuals must be native English speakers and should not have any previous neurological or psychiatric conditions before their stroke. Participants will engage in assessments that will help researchers learn more about language impairments following a stroke. This study is important because it aims to improve our understanding of aphasia and potentially lead to better ways to help those who struggle with communication after a stroke. If you or someone you know fits the eligibility criteria and is interested, this could be a meaningful way to contribute to important research in this field.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • At least 18 years of age
- • Persons with acquired aphasia are defined as those with a language impairment following left hemisphere brain injury (most likely a stroke).
- • Neurotypical adults need to be either young (ages 18-30 years) or older (\> 60 years)
- • Native (or primary) speakers of English
- Exclusion Criteria:
- • Prior neurological or psychiatric diagnoses or developmental disabilities before the onset of aphasia
- • do not speak English fluently
About University Of Maryland, College Park
The University of Maryland, College Park, is a leading research institution dedicated to advancing knowledge and innovation in various fields, including health and medicine. As a prominent clinical trial sponsor, the university leverages its extensive resources, interdisciplinary expertise, and commitment to rigorous scientific inquiry to facilitate impactful clinical research. The institution fosters collaborations among faculty, healthcare professionals, and industry partners to enhance patient care and drive advancements in medical science, ensuring compliance with ethical standards and regulatory requirements throughout the research process.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
College Park, Maryland, United States
Patients applied
Trial Officials
Yasmeen Faroqi-Shah, PhD
Principal Investigator
University of Maryland
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported